Floatz logo

Mezigdomide

PMD

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the PMD cohort.

Asset / SponsorPhaseRating
Elranatamab
M.D. Anderson Cancer Center
Phase 2CCC
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 2CCC
Benadryl
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

Mezigdomide is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
66 / 100
View asset →
ElranatamabDormant
B
Indicative ·
57 / 100
View asset →
BCMADormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →